EXHIBIT 3.1
| 1 |
| 2 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2021
| Creative Medical Technology Holdings, Inc. |
| (Exact name of registrant as specified in its charter) |
| Nevada |
| 000-53500 |
| 88-0622284 |
| (State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification Number) |
3008 W Lupine Ave, Phoenix, AZ 85029
(Address of principal executive offices)
(602) 680-7439
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.03 Material Modification to Rights of Security Holders.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On March 11, 2021, following the approval of the Board of Directors of Creative Medical Technology Holdings, Inc., a Nevada corporation (the “Company”), and the sole holder of Company’s Series A Preferred Stock, the Company filed a Certificate of Amendment to the Certificate of Designation of the Company’s Series A Preferred Stock with the Secretary of State of the State of Nevada (the “Certificate of Amendment”). The Certificate of Amendment increased the voting power of the Series A Preferred Stock to 1,000 votes per share from 30 votes per share. The Company has 3,000,000 shares of Series A Preferred Stock outstanding, all of which are held by Timothy Warbington, the Company’s Chief Executive Officer.
The information set forth above is qualified in its entirety by reference to the actual terms of the Certificate of Amendment, which has been filed as Exhibit 3.1 hereto and which is incorporated herein by reference.
Item 8.01. Other Events
On March 10, 2021, the Company issued a press release announcing that it has started recruitment of clinical sites at which patients will be treated with its StemSpine® Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
| ||
|
|
|
|
|
|
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| Creative Medical Technology Holdings, Inc. |
| |
|
|
| ||
| Date: March 12, 2021 | By: | /s/ Timothy Warbington |
|
|
|
| Timothy Warbington, Chief Executive Officer |
|
| 3 |
EXHIBIT 3.1
| 1 |
| 2 |
EXHIBIT 99.1
Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites
March 10, 2021 Phoenix, AZ, – Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for StemSpine®.
StemSpine®, the company’s patented Regenerative Stem Cell Procedure for Treatment of Degenerative Disc Disease (DDD), showed high efficacy with no adverse effects reported in previous PR (results summarized below).
| Total Patients | 15 |
| Pain Threshold Average after 30 days from 8.9 Baseline | 4.3 - 52% Less Pain |
| Pain Threshold Average after 6 Months from 8.9 Baseline | 1.8 - 80% Less Pain |
| Pain Threshold Average after 12 Months from 8.9 Baseline | 1.3 - 85% Less Pain |
The company will seek out locations across the USA geographically dispersed to provide maximum access to potential patients. Patient recruitment will begin immediately upon signing of the first clinical site. The first 100 patients recruited in the USA will be followed-up with in a similar cadence as showcased above (30 days; 6 months; 12 months) and all data will be entered into a clinical registry and overseen by an independent board in preparation for publication in peer-reviewed journal.
“We are excited to bring this life changing procedure to the millions of Americans that experience DDD every year”, said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. “We have heard from hundreds of patients through our website (www.stemspine.com) regarding how debilitating lower back pain can be, and we are proud to be the first and only company to deliver a validated autologous, bone marrow derived stem cell based procedure to help improve their lives. For our shareholders, StemSpine® represents a multi-billion-dollar market in which current medical solutions do not address the underlying cause and where treated patients will be our biggest advocates.”
The company was granted United States Patent #9,598,673 which covers the use of any mesenchymal stem cells, both from the patient (autologous) or from donors (allogeneic), for reduction of lower back pain when injected into the major muscles of the lower back.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in regenerative medicine-stem cell technology in the fields of immunotherapy, urology, neurology and orthopedics and listed on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.
Creative Medical Technology Holdings, Inc.
CEO@creativemedicalhealth.com